Matthew Totter
Family · Albuquerque, NMNPI 1396224390
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.7% of the total across 258 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 28 manufacturers reported payments, led by AstraZeneca at 24.2% of the total. Among family clinicians in NM with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 258 payments — averaging $23.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$1K
- AbbVie$1K
- Novo Nordisk$917
- Lilly USA, LLC$540
- Amgen$318
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$227
- plus $1K from 22 others
What the payments were for
- Food & beverage$6,035100%
- Education$170%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 35 | $1,465 |
| AbbVie | 79 | $1,215 |
| Novo Nordisk | 26 | $917 |
| Lilly USA, LLC | 32 | $540 |
| Amgen(2 entities) | 14 | $318 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 18 | $227 |
| Boehringer Ingelheim | 4 | $210 |
| Teva Pharmaceuticals USA, Inc. | 4 | $181 |
| Exact Sciences | 10 | $181 |
| Novartis | 9 | $176 |
| Nevro Corp. | 2 | $170 |
| Pfizer | 4 | $69 |
| Otsuka America Pharmaceutical, Inc. | 3 | $61 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $43 |
| Biohaven Pharmaceuticals, Inc. | 2 | $38 |
| Baxter Healthcare | 1 | $26 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $25 |
| E.r. Squibb & Sons, L.L.C. | 1 | $21 |
| Itamar Medical Inc | 2 | $21 |
| Lundbeck LLC | 1 | $20 |
| Daiichi Sankyo Inc. | 1 | $19 |
| Irhythm Technologies, Inc. | 1 | $19 |
| Amarin Pharma, Inc. | 1 | $17 |
| GSK | 1 | $16 |
| Acella Pharmaceuticals, LLC | 1 | $15 |
| Abbott | 1 | $14 |
| Phathom Pharmaceuticals, Inc. | 1 | $14 |
| Ferring Pharmaceuticals Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$6,052 in reported general payments places this provider in the 95th percentile of 1,080 family providers in New Mexico.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RybelsusSemaglutide | 23 | $33,634 |
| JardianceEmpagliflozin | 22 | $22,760 |
| MounjaroTirzepatide | 17 | $17,750 |
| TrulicityDulaglutide | 17 | $17,348 |
| FarxigaDapagliflozin Propanediol | 13 | $16,673 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 11 | $5,509 |
| Levothyroxine Sodium | 106 | $2,632 |
| BreynaBudesonide/Formoterol Fumarate | 12 | $2,495 |
| Tamsulosin Hcl | 55 | $1,027 |
| Atorvastatin Calcium | 76 | $1,020 |
| Pregabalin | 11 | $931 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 32 | $893 |
| Omeprazole | 39 | $846 |
| Losartan Potassium | 51 | $770 |
| Gabapentin | 41 | $720 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $540 | $35,09934 claims |
| Novo NordiskRybelsus | $917 | $33,63423 claims |
| Boehringer IngelheimJardiance, Combivent Respimat | $210 | $28,26833 claims |
| AstraZenecaFarxiga | $1,465 | $16,67313 claims |
| Acella Pharmaceuticals, LLCNp Thyroid | $15 | $68012 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,080 family providers in New Mexico.
Other family in Albuquerque
- Barbara FranklinAlbuquerque$28K
- Melanie DuranAlbuquerque$15K
- Irasema LlewellynAlbuquerque$14K
- Charles GallegosAlbuquerque$10K
- Marlyn NewbyAlbuquerque$9K
- Annmarie FoleyAlbuquerque$8K
- Aimee CasarezAlbuquerque$7K
- Rita SuharliAlbuquerque$6K
- Roberta ChampouillonAlbuquerque$6K
- Genevieve DavisAlbuquerque$6K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.